<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889573</url>
  </required_header>
  <id_info>
    <org_study_id>87RI20_0074 (R2IGH)</org_study_id>
    <nct_id>NCT04889573</nct_id>
  </id_info>
  <brief_title>Immunoglobulin Gene Rearrangement and Repair in Healthy Donors</brief_title>
  <acronym>R2IGH</acronym>
  <official_title>Immunoglobulin Gene Rearrangement and Repair in Healthy Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      B-cells ensure humoral immune response against antigens (Ag) thanks to their receptor (BCR).&#xD;
      V(D)J rearrangement, somatic hypermutation, immunoglobulin (Ig) class switch and locus&#xD;
      suicide recombination are mutational/recombinational processes targeting Ig loci influencing&#xD;
      BCR expression. Study of these events is essential for B cell function analysis. Our project&#xD;
      will provide the normal reference values using high throughput sequencing-based protocols.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Actual">October 14, 2021</completion_date>
  <primary_completion_date type="Actual">October 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of use of the V, D and J genes in VDJ rearrangements</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of HyperMutation Somatic (SHM) in VDJ regions</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature of HyperMutation Somatic (SHM)</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>transitions and transversions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ig class switching (CSR) and recombination suicide of the IgH locus (LSR) junctions</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>number of CSR and LSR junctions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of g class switching (CSR) and recombination suicide of the IgH locus (LSR) junctions</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>frequency of CSR and LSR junctions according to their structure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Blood sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA</description>
    <arm_group_label>Blood sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy volunteers aged between 18 and 70&#xD;
&#xD;
          -  volunteers free from lymphoid hemopathy, immune deficiency and autoimmune disease.&#xD;
&#xD;
             3 categories : volunteers between 18 and 34 years of age, volunteers between 35 and 50&#xD;
             years of age, volunteers between 51 and 69 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any recent vaccination (&lt; 4 weeks)&#xD;
&#xD;
          -  tumoral pathology&#xD;
&#xD;
          -  lymphoïd hemopathy&#xD;
&#xD;
          -  immune deficiency&#xD;
&#xD;
          -  autoimmune disease&#xD;
&#xD;
          -  transplanted patients&#xD;
&#xD;
          -  inflammatory / systemic diseases&#xD;
&#xD;
          -  hypersensitivity or allergies&#xD;
&#xD;
          -  treatments likely to modify the immune response :&#xD;
&#xD;
               -  calcineurin inhibitors: ciclosporin, tacrolimus -antimetabolite: azathioprine,&#xD;
                  mycophenolate mofetil / mycophenolic acid, 6-mercaptopurine, methotrexate&#xD;
&#xD;
               -  cyclophosphamide&#xD;
&#xD;
               -  antilymphocyte serum (rabbit, horse)&#xD;
&#xD;
               -  mTOR inhibitors: everolimus, sirolimus&#xD;
&#xD;
               -  anti-CD25 (anti IL2-R): basiliximab, dacliximab -belatacept (anti CD80-86)&#xD;
&#xD;
               -  abatacept (CTLA4-Ig)&#xD;
&#xD;
               -  OKT3 (Muronomab-CD3, anti-CD23)&#xD;
&#xD;
               -  glucocorticoids: methylprednisolone, prednisone, prednisolone.&#xD;
&#xD;
               -  entuzumab (anti-CD52)&#xD;
&#xD;
               -  rituximab, ocrelizumab (anti-CD20)&#xD;
&#xD;
               -  eculizumab (anti-C5)&#xD;
&#xD;
               -  anakinra (analogue IL1-RA)&#xD;
&#xD;
               -  leflunomide (dihydroorotate dehydrogenase inhibition)&#xD;
&#xD;
               -  bortezomib (proteasome inhibitor)&#xD;
&#xD;
               -  fingolimod (S1P receptor antagonist)&#xD;
&#xD;
               -  alentuzumab (anti CD52)&#xD;
&#xD;
               -  Ig G -antiTNF (etanercept, infliximab, adalimumab, certolizumab)&#xD;
&#xD;
               -  vedolizumab (Anti-integrin α4β7 Ab)&#xD;
&#xD;
               -  ustekinumab (anti-IL12)&#xD;
&#xD;
               -  natalizumab (anti-integrin a4)&#xD;
&#xD;
               -  mitoxantrone (topoisomerase type II inhibitor)&#xD;
&#xD;
               -  tocilizumab (anti-IL6)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cells</keyword>
  <keyword>BCR</keyword>
  <keyword>VDJ rearrangement</keyword>
  <keyword>SHM</keyword>
  <keyword>CSR</keyword>
  <keyword>LSR</keyword>
  <keyword>Ig</keyword>
  <keyword>HTS</keyword>
  <keyword>normal values</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

